The Mononucleosis Diagnostic Market size was estimated USD 1.7 billion in 2022 and is expected to reach USD 3.2 billion by 2030 at a CAGR of 8.6% during the forecast period of 2023-2030.
Mononucleosis is an infectious disease conveyed by the Epstein-Barr virus through saliva. Early detection allows for effective infection therapy, necessitating the use of mononucleosis diagnostics. The advantages of mononucleosis diagnostics, such as exact diagnosis, faultless detection, and accurate results, may lead to promising growth prospects. All of these variables could help the mononucleosis diagnostic market flourish.
DRIVERS
Increasing teenager population is laying the foundation for expansion
The growing adolescent population worldwide is also a crucial element driving market expansion, as mononucleosis is most common in teenagers and adults. Asia is home to more than half of the world's adolescents. South Asia has the most teenagers of any region, with almost 350 million. With almost 300 million people, it is followed by East Asia and the Pacific. In either of these places, the teenage population eclipses that of any other region on the planet. According to a World Health Organization (WHO) report, nearly 1.2 billion adolescents (10-19 years old) live in the world. Teenagers represent for a quarter of the population in some countries, and the number of adolescents is predicted to climb until 2050, primarily in low- and middle-income countries (LMICs), where close to 90% of 10- to 19-year-olds live.
RESTRAIN
Patients lack of knowledge about the availability and benefits of modern diagnostic tests.
OPPORTUNITY
The rising prevalence of infectious mononucleosis is driving expansion.
The increasing prevalence of infectious mononucleosis (IM), rising awareness and information about mononucleosis, and increased research and development activities for IM diagnosis and treatment are the primary drivers driving the global mononucleosis diagnostic market.
CHALLENGES
The high cost of mononucleosis diagnostics will provide a hurdle to the market.
The high cost of mononucleosis diagnostics and poor acceptance rate in emerging and developing nations may stymie industry expansion. Some constraints connected with mononucleosis diagnostic tests are projected to impede market expansion throughout the projection period. There are just three tests that can diagnose mononucleosis, which is extremely low given the rate at which infectious mononucleosis is spreading.
Even in peacetime, the Ukrainian healthcare system was far from ideal. People suffering from chronic ailments frequently experienced pauses in medication supplies, doctors complained about inadequate pay, and hospital extortions had long ceased to be shocking. The conflict had every opportunity of utterly destroying the system, but instead spurred the government and local specialists to find effective solutions, due to which medicine in the country not only survived, but also continued to improve. Doctors must work in the outdoors, substituting sterile operating rooms with cellars and bomb shelters. In certain cities, the medical personnel does not leave the hospital, which has become their second home.
IMPACT OF ONGOING RECESSION
The diagnostic sector confronts a "challenging set-up" in 2022, as persistent recession in the United States and Europe dampens chances for a post-pandemic volume recovery. Analysts said there will be "limited visibility over the course of the year" as corporations report second-quarter results, and that businesses may need to focus more on demonstrating their paths to profitability in a more tough macro environment. Changes in market mood, along with the possibility of a recession, may make it more difficult for businesses to raise finance. According to the experts, Invitae has a "tighter cash picture."
By Test Type
Infectious Mononucleosis (IM) Test
Epstein-Barr Virus (EBV) Test
Others
In 2022, infectious mononucleosis (IM) test segment is expected to held the highest market share during the forecast period due to the prevalence of infectious mononucleosis is rapidly increasing, there is an increase in demand for diagnostics, which is driving revenue growth in this field. The Epstein-Barr virus (EBV), which causes IM and is exceedingly common around the world, also adds to the rising need for IM testing. A blood sample is frequently used in the IM test, and it is checked for the presence of specific antibodies produced by the body in response to the virus. This test, which is widely available, is the most commonly used approach for diagnosing IM.
By End User
Hospitals
Diagnostic Laboratories
Others
.png)
In 2022, the hospitals segment is expected to dominate the market growth during the forecast period because of the availability of a variety of diagnostic tests, advanced imaging technology, and the presence of highly experienced healthcare workers. Furthermore, hospitals are outfitted with modern equipment and specialized departments that allow for rapid and accurate disease diagnosis.
North America held a significant market share in 2022 owing to the increased prevalence of mononucleosis and other viral illnesses, the presence of a well-established healthcare infrastructure, and the widespread adoption of cutting-edge diagnostic technologies. The increasing demand for early and accurate mononucleosis diagnoses, as well as growing public awareness of the importance of fast diagnosis and treatment, are the primary drivers of this region's mononucleosis diagnostic market expansion. The United States and Canada are the two countries most responsible for the market's expansion in this region.
Asia Pacific is witness to expand fastest CAGR rate during the forecast period owing to the region's growing adolescent population and the increased incidence of infectious mononucleosis (IM). According to UNICEF figures, Asia is home to more than half of all adults worldwide, with South Asia having the most adolescents of any area in the globe.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Daiichi, Digene, Hemagen, Meridian, Gene-Tac, Biotest, Abbott Laboratories, Bio-Rad, Genzyme, Roche, Johnson & Johnson, Becton Dickinson, Diasorin, Beckman Coulter, and Others.
Orthofix Medical Inc., will develop Opus BA for cervical and lumbar spine fusion surgeries in February 2022. Opus BA acts as a scaffold, allowing bone to grow over the surface before being reabsorbed and replaced with normal bone during healing.
In 2021, Abbott Laboratories purchased Walk Vascular, LLC, a medical device business focusing on developing minimally invasive devices for vascular disease, in order to extend its vascular portfolio.
|
Report Attributes |
Details |
|
Market Size in 2022 |
US$ 1.7 billion |
|
Market Size by 2030 |
US$ 3.2 billion |
|
CAGR |
CAGR of 8.6% From 2023 to 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023-2030 |
|
Historical Data |
2019-2021 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
• By Test Type (Infectious Mononucleosis (IM) Test, Epstein-Barr Virus (EBV) Test, Others) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
|
Company Profiles |
Daiichi, Digene, Hemagen, Meridian, Gene-Tac, Biotest, Abbott Laboratories, Bio-Rad, Genzyme, Roche, Johnson & Johnson, Becton Dickinson, Diasorin, Beckman Coulter |
|
Market Opportunities |
• The rising prevalence of infectious mononucleosis is driving expansion. |
|
Market Challenges |
•The high cost of mononucleosis diagnostics will provide a hurdle to the market. |
The rising prevalence of infectious mononucleosis is driving expansion.
Mononucleosis Diagnostic Market size was valued at USD 1.7 billion in 2022.
The growth rate of Mononucleosis Diagnostic Market is expected to grow USD 3.2 billion by 2030.
Mononucleosis Diagnostic Market is anticipated to expand by 8.6% from 2023 to 2030.
Infectious mononucleosis (IM) test segment is expected to held the highest market share in 2022.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Mononucleosis Diagnostic Market Segmentation, By Test Type
8.1 Infectious Mononucleosis (IM) Test
8.2 Epstein-Barr Virus (EBV) Test
8.3 Others
9. Mononucleosis Diagnostic Market Segmentation, By End User
9.1 Hospitals
9.2 Diagnostic Laboratories
9.3 Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Mononucleosis Diagnostic Market by Country
10.2.2North America Mononucleosis Diagnostic Market by Test Type
10.2.3 North America Mononucleosis Diagnostic Market by End User
10.2.4 USA
10.2.4.1 USA Mononucleosis Diagnostic Market by Test Type
10.2.4.2 USA Mononucleosis Diagnostic Market by End User
10.2.5 Canada
10.2.5.1 Canada Mononucleosis Diagnostic Market by Test Type
10.2.5.2 Canada Mononucleosis Diagnostic Market by End User
10.2.6 Mexico
10.2.6.1 Mexico Mononucleosis Diagnostic Market by Test Type
10.2.6.2 Mexico Mononucleosis Diagnostic Market by End User
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Eastern Europe Mononucleosis Diagnostic Market by Country
10.3.1.2 Eastern Europe Mononucleosis Diagnostic Market by Test Type
10.3.1.3 Eastern Europe Mononucleosis Diagnostic Market by End User
10.3.1.4 Poland
10.3.1.4.1 Poland Mononucleosis Diagnostic Market by Test Type
10.3.1.4.2 Poland Mononucleosis Diagnostic Market by End User
10.3.1.5 Romania
10.3.1.5.1 Romania Mononucleosis Diagnostic Market by Test Type
10.3.1.5.2 Romania Mononucleosis Diagnostic Market by End User
10.3.1.6 Hungary
10.3.1.6.1 Hungary Mononucleosis Diagnostic Market by Test Type
10.3.1.6.2 Hungary Mononucleosis Diagnostic Market by End User
10.3.1.7 Turkey
10.3.1.7.1 Turkey Mononucleosis Diagnostic Market by Test Type
10.3.1.7.2 Turkey Mononucleosis Diagnostic Market by End User
10.3.1.8 Rest of Eastern Europe
10.3.1.8.1 Rest of Eastern Europe Mononucleosis Diagnostic Market by Test Type
10.3.1.8.2 Rest of Eastern Europe Mononucleosis Diagnostic Market by End User
10.3.2 Western Europe
10.3.2.1 Western Europe Mononucleosis Diagnostic Market by Country
10.3.2.2 Western Europe Mononucleosis Diagnostic Market by Test Type
10.3.2.3 Western Europe Mononucleosis Diagnostic Market by End User
10.3.2.4 Germany
10.3.2.4.1 Germany Mononucleosis Diagnostic Market by Test Type
10.3.2.4.2 Germany Mononucleosis Diagnostic Market by End User
10.3.2.5 France
10.3.2.5.1 France Mononucleosis Diagnostic Market by Test Type
10.3.2.5.2 France Mononucleosis Diagnostic Market by End User
10.3.2.6 UK
10.3.2.6.1 UK Mononucleosis Diagnostic Market by Test Type
10.3.2.6.2 UK Mononucleosis Diagnostic Market by End User
10.3.2.7 Italy
10.3.2.7.1 Italy Mononucleosis Diagnostic Market by Test Type
10.3.2.7.2 Italy Mononucleosis Diagnostic Market by End User
10.3.2.8 Spain
10.3.2.8.1 Spain Mononucleosis Diagnostic Market by Test Type
10.3.2.8.2 Spain Mononucleosis Diagnostic Market by End User
10.3.2.9 Netherlands
10.3.2.9.1 Netherlands Mononucleosis Diagnostic Market by Test Type
10.3.2.9.2 Netherlands Mononucleosis Diagnostic Market by End User
10.3.2.10 Switzerland
10.3.2.10.1 Switzerland Mononucleosis Diagnostic Market by Test Type
10.3.2.10.2 Switzerland Mononucleosis Diagnostic Market by End User
10.3.2.11 Austria
10.3.2.11.1 Austria Mononucleosis Diagnostic Market by Test Type
10.3.2.11.2 Austria Mononucleosis Diagnostic Market by End User
10.3.2.12 Rest of Western Europe
10.3.2.12.1 Rest of Western Europe Mononucleosis Diagnostic Market by Test Type
10.3.2.12.2 Rest of Western Europe Mononucleosis Diagnostic Market by End User
10.4 Asia-Pacific
10.4.1 Asia Pacific Mononucleosis Diagnostic Market by Country
10.4.2 Asia Pacific Mononucleosis Diagnostic Market by Test Type
10.4.3 Asia Pacific Mononucleosis Diagnostic Market by End User
10.4.4 China
10.4.4.1 China Mononucleosis Diagnostic Market by Test Type
10.4.4.2 China Mononucleosis Diagnostic Market by End User
10.4.5 India
10.4.5.1 India Mononucleosis Diagnostic Market by Test Type
10.4.5.2 India Mononucleosis Diagnostic Market by End User
10.4.6 Japan
10.4.6.1 Japan Mononucleosis Diagnostic Market by Test Type
10.4.6.2 Japan Mononucleosis Diagnostic Market by End User
10.4.7 South Korea
10.4.7.1 South Korea Mononucleosis Diagnostic Market by Test Type
10.4.7.2 South Korea Mononucleosis Diagnostic Market by End User
10.4.8 Vietnam
10.4.8.1 Vietnam Mononucleosis Diagnostic Market by Test Type
10.4.8.2 Vietnam Mononucleosis Diagnostic Market by End User
10.4.9 Singapore
10.4.9.1 Singapore Mononucleosis Diagnostic Market by Test Type
10.4.9.2 Singapore Mononucleosis Diagnostic Market by End User
10.4.10 Australia
10.4.10.1 Australia Mononucleosis Diagnostic Market by Test Type
10.4.10.2 Australia Mononucleosis Diagnostic Market by End User
10.4.11 Rest of Asia-Pacific
10.4.11.1 Rest of Asia-Pacific Mononucleosis Diagnostic Market by Test Type
10.4.11.2 Rest of Asia-Pacific APAC Mononucleosis Diagnostic Market by End User
10.5 Middle East & Africa
10.5.1 Middle East
10.5.1.1 Middle East Mononucleosis Diagnostic Market by Country
10.5.1.2 Middle East Mononucleosis Diagnostic Market by Test Type
10.5.1.3 Middle East Mononucleosis Diagnostic Market by End User
10.5.1.4 UAE
10.5.1.4.1 UAE Mononucleosis Diagnostic Market by Test Type
10.5.1.4.2 UAE Mononucleosis Diagnostic Market by End User
10.5.1.5 Egypt
10.5.1.5.1 Egypt Mononucleosis Diagnostic Market by Test Type
10.5.1.5.2 Egypt Mononucleosis Diagnostic Market by End User
10.5.1.6 Saudi Arabia
10.5.1.6.1 Saudi Arabia Mononucleosis Diagnostic Market by Test Type
10.5.1.6.2 Saudi Arabia Mononucleosis Diagnostic Market by End User
10.5.1.7 Qatar
10.5.1.7.1 Qatar Mononucleosis Diagnostic Market by Test Type
10.5.1.7.2 Qatar Mononucleosis Diagnostic Market by End User
10.5.1.8 Rest of Middle East
10.5.1.8.1 Rest of Middle East Mononucleosis Diagnostic Market by Test Type
10.5.1.8.2 Rest of Middle East Mononucleosis Diagnostic Market by End User
10.5.2 Africa
10.5.2.1 Africa Mononucleosis Diagnostic Market by Country
10.5.2.2 Africa Mononucleosis Diagnostic Market by Test Type
10.5.2.3 Africa Mononucleosis Diagnostic Market by End User
10.5.2.4 Nigeria
10.5.2.4.1 Nigeria Mononucleosis Diagnostic Market by Test Type
10.5.2.4.2 Nigeria Mononucleosis Diagnostic Market by End User
10.5.2.5 South Africa
10.5.2.5.1 South Africa Mononucleosis Diagnostic Market by Test Type
10.5.2.5.2 South Africa Mononucleosis Diagnostic Market by End User
10.5.2.6 Rest of Africa
10.5.2.6.1 Rest of Africa Mononucleosis Diagnostic Market by Test Type
10.5.2.6.2 Rest of Africa Mononucleosis Diagnostic Market by End User
10.6 Latin America
10.6.1 Latin America Mononucleosis Diagnostic Market by Country
10.6.2 Latin America Mononucleosis Diagnostic Market by Test Type
10.6.3 Latin America Mononucleosis Diagnostic Market by End User
10.6.4 Brazil
10.6.4.1 Brazil Mononucleosis Diagnostic Market by Test Type
10.6.4.2 Brazil Africa Mononucleosis Diagnostic Market by End User
10.6.5 Argentina
10.6.5.1 Argentina Mononucleosis Diagnostic Market by Test Type
10.6.5.2 Argentina Mononucleosis Diagnostic Market by End User
10.6.6 Colombia
10.6.6.1 Colombia Mononucleosis Diagnostic Market by Test Type
10.6.6.2 Colombia Mononucleosis Diagnostic Market by End User
10.6.7 Rest of Latin America
10.6.7.1 Rest of Latin America Mononucleosis Diagnostic Market by Test Type
10.6.7.2 Rest of Latin America Mononucleosis Diagnostic Market by End User
11 Company Profile
11.1 Daiichi
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Product/Services Offered
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Digene
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Product/Services Offered
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 Hemagen
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Product/Services Offered
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Meridian
11.4 Company Overview
11.4.2 Financials
11.4.3 Product/Services Offered
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Gene-Tac, Biotest
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Product/Services Offered
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Abbott Laboratories
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Product/Services Offered
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Bio-Rad
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Product/Services Offered
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Genzyme
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Product/Services Offered
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Roche
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Product/Services Offered
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Johnson & Johnson
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Product/Services Offered
11.10.4 SWOT Analysis
11.10.5 The SNS View
11.11 Becton Dickinson
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Product/Services Offered
11.11.4 SWOT Analysis
11.11.5 The SNS View
11.12 Diasorin
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Product/Services Offered
11.12.4 SWOT Analysis
11.12.5 The SNS View
11.13 Beckman Coulter
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Product/Services Offered
11.13.4 SWOT Analysis
11.13.5 The SNS View
12. Competitive Landscape
12.1 Competitive Bench marking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. USE Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Wireless Health Market Size was valued at USD 210.54 billion in 2023 and is expected to reach USD 1160.97 billion by 2031 and grow at a CAGR of 23.79% over the forecast period 2024-2031.
The Magnetic Resonance Imaging (MRI) Market was valued at USD 5.4 Bn in 2022 and is expected to reach USD 8.93 Bn by 2030 and grow at a CAGR of 6.5% during the forecasted period 2023-2030.
The Laboratory Information Management System (LIMS) Market Size was valued at USD 2.05 billion in 2022, and is expected to reach USD 3.69 billion by 2030 and grow at a CAGR of 7.6% over the forecast period 2023-2030.
The Nebulizer Market was estimated at USD 1.14 billion in 2023 and is poised to reach at 1.83 billion in 2031 anticipated to expand at a compound annual growth rate approx. CAGR of 6.07% for the forecast period of 2024-2031.
In 2022, The Skin Cancer Treatment Market size amounted to USD 9.98 Billion & is estimated to reach USD 18.06 Billion by 2030 and increase at a compound annual growth rate of 7.7% between 2023 and 2030.
The Defibrillator Market size was estimated at USD 7.07 billion in 2023 and is expected to reach USD 13.98 billion by 2031 at a CAGR of 8.71% during the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
